Free Newsletter
Pfizer funds Canadian CME, prompting outcry
As some big-name hospitals and drugmakers back away from industry-funded medical education, the Canadian Medical Association has anted up. The CMA has teamed up with Pfizer on a nationwide educational campaign, backed by $780,000 in Pfizer funding. Predictably, the move has ignited criticism from ethicists and others. "[T]he pharmaceutical industry has no business at all educating doctors," Arnold Relman, professor emeritus at Harvard Medical School and former NEJM editor, told the Globe and Mail.
But the CMA says it's well able to keep Pfizer at arm's length from the new CME classes. The money won't influence the content--nor will the two Pfizer staffers who'll sit on a six-member administrative board charged with supervising and evaluating the program. "There's no connection between the funder and the people who are actually providing the content," said the CMA's Dr. Sam Shortt (as quoted by the Globe and Mail).
Nonetheless, Relman and others don't buy it. "[I]f you're paying the piper, you influence the tune," Relman contends. "Even under the best circumstances, there is the potential for influence," said Michael Steinman of the University of California at San Francisco. Think about it, Relman says: Why would Pfizer spend that money if it wasn't getting something out of it?
Well, there's been plenty of debate on that score. And though some teaching hospitals are taking a hard line on industry-funded CME, and drugmakers such as GlaxoSmithKline have backed away a bit from paying for commercially produced courses, the jury's still out. Some doctors take offense at the very idea that they'd be corrupted by pharma-funded education. And the American Medical Association has had the chance to ban industry-backed CME--twice--and has voted against it both times.
- read the Globe and Mail piece
Related Articles:
Glaxo to stop funding commercial CME
Merck, Schering spent $60M on CME
Pharma-funded CME gets the lash
AMA won't ban industry-funded education
Comments
The mere fact that two people from Pfizer are sitting on the board demonstrates an influence to content and structure. Pfizer is buying insurance to make sure that nothing disadvantages their product opportunity in the marketplace. I'm surprized that this passed the legal and regulatory review committee, which evaluates sponsorship merit. Is this Jeff Kindler's definition of turning over a new leaf?
Because Pfizer thinks it can make money doing this certainly does not mean they will make money. I think Pfizer has been pretty good of late to show everyone how to loose, not make, money. GSK are shying away probably because the have better places to put their money than some PR exercise.
And maybe out of context, but to say "The pharmaceutical industry has no business educating doctors" is pretty narrow-minded and lacking perspective. How many hours does a Harvard medical student have dedicated to Pharmacology anyway? I'll take a wild guess: 32 hours from walking in the front door to out the back with your MD in pocket, and probably not a whole lot more. And if you're going to say Pharmacology is not the place to learn about drugs, then that would be as senseful as saying Anatomy is not the place to learn about the body. So if the medical schools do not do it, who is going to do it? I'd rather have the companies peddle their info than no one at all - as long as it's upfront and a reasonable reflection of the truth. Doctors aren't idiots. Greedy, yes, probably (who was it that accepted these $3/4M?); stupid, no.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: